Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/21/26
Alkermes' Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim AnalysisBusiness Wire • 07/13/26
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026Business Wire • 06/17/26
ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & EuropeZacks Investment Research • 06/16/26
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and EuropeBusiness Wire • 06/15/26
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition NearsMarketBeat • 06/10/26
Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/04/26
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine ResearchBusiness Wire • 06/04/26
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness Wire • 06/03/26
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual MeetingBusiness Wire • 05/26/26
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific ConferencesBusiness Wire • 05/21/26
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic HypersomniaBusiness Wire • 05/12/26
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/05/26